Ultragenyx Pharmaceutical Inc (FRA:UP0)
€ 46.2 -0.4 (-0.86%) Market Cap: 4.31 Bil Enterprise Value: 3.76 Bil PE Ratio: 0 PB Ratio: 13.42 GF Score: 81/100

Ultragenyx Pharmaceutical Inc and GeneTx Biotherapeutics LLC GTX-102 Interim Data and Program Update Call Transcript

Jul 18, 2022 / 09:00PM GMT
Release Date Price: €64 (-0.78%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Ultragenyx GTX-102 for Angelman syndrome interim data and program update Conference Call. (Operator Instructions)

It is now my pleasure to turn today call over to Joshua Higa, Executive Director and Head of Investor Relations. You may begin.

Joshua Higa
Ultragenyx Pharmaceutical Inc. - Director of IR & Corporate Communications

Thank you. We issued a press release and posted slides that detail this interim data and program update, which you can find on our website at ir.ultragenyx.com.

Joining me on this call from the company are Emil Kakkis, Chief Executive Officer and President; Camille Bedrosian, Chief Medical Officer; Scott Stromatt, Chief Medical Officer of Neurology; Mardi Dier, Chief Financial Officer; and Tom Kassberg, Chief Business Officer.

I'm also pleased to be joined on this call by 2 investigators on our study: Dr. Erick Sell, Associate Professor Neurology at Children's Hospital of Eastern Ontario in Ottawa, Canada; and Dr. Elizabeth Berry-Kravis,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot